Brief: Skye Reports Positive Cbeyond Phase 2A Extension Interim Study Results For Nimacimab
02/02/2026 12:26
Feb 2 (Reuters) - Skye Bioscience Inc SKYE.O: SKYE REPORTS POSITIVE CBEYOND PHASE 2A EXTENSION INTERIM STUDY RESULTS FOR NIMACIMAB IN COMBINATION WITH SEMAGLUTIDE SKYE BIOSCIENCE INC - 22.3% WEIGHT LOSS AT 52 WEEKS WITH NIMACIMAB + SEMAGLUTIDE (2.4 MG) COMBINATION SKYE BIOSCIENCE INC - FULL TOPLINE REPORTING OF CBEYOND PHASE 2A DATA EXPECTED Q3 2026 Source text: ID:nGNXc9xN7x Further company coverage: SKYE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Skye Bioscience
See all newsBrief: Skye Announces Cohort Review Committee Approved Opening Of Cohort 2 Based On Favorable Safety Data From First Four Participants Treated In Cohort 1
U.S. RESEARCH ROUNDUP-Accuray, Aevex, Zoetis
U.S. STOCKS ON THE MOVE-Tesla, Blue Owl, Ford
U.S. STOCKS ON THE MOVE-Energy firms, Estee Lauder, HMH Holding
Skye Bioscience rises as it begins testing higher doses of obesity drug